

Rev 1: September 2018
FSN Ref: FSN-2026-003
Date: 31 March 2026

Urgent Field Safety Notice

YEASTONE BROTH, 11ML, 10/BOX (YY3462)

For Attention of*: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)*
Confidential business information

Rev 1: September 2018
FSN Ref: FSN-2026-003

Urgent Field Safety Notice (FSN)

YEASTONE BROTH, 11ML, 10/BOX (YY3462)

1. Information on Affected Devices*													
1.	1. Device Type(s)*												
	IVD												
1.	2. Commercial name(s)												
	Yeastone Broth, 11ml, 10/Box												
1.	3. Unique Device Identifier(s) (UDI-DI)												
	848838018817												
1.	4. Primary clinical purpose of device(s)*												
	Yeastone Broth, 11ml, 10/Box (YY3462) is an antibiotic susceptibility testing of mycological clinical specimens.												
1.	5. Device Model/Catalogue/part number(s)*												
	YY3462												
1.	6. Software version												
	N/A												
1.	7. Affected serial or lot number range												
	<table><tr><th>Kit Lot Number</th></tr><tr><td>321046</td></tr><tr><td>329835</td></tr><tr><td>330316</td></tr><tr><td>327069</td></tr><tr><td>330317</td></tr><tr><td>336325</td></tr><tr><td>338314</td></tr><tr><td>341161</td></tr><tr><td>303851</td></tr><tr><td>311723</td></tr></table>	Kit Lot Number	321046	329835	330316	327069	330317	336325	338314	341161	303851	311723	
Kit Lot Number													
321046													
329835													
330316													
327069													
330317													
336325													
338314													
341161													
303851													
311723													
1.	8. Associated devices												
	N/A												

2. Reason for Field Safety Corrective Action (FSCA)*	
2.	1. Description of the product problem* Remel Inc., part of Thermo Fisher Scientific, received ten customers' complaints reporting performance issues of Yeastone Broth, 11ml, 10/Box, YY3462, lots 321046, 329835, 330316, 327069, 330317, 336325, 338314, 341161, 303851, 311723. There were no reports of illness/injury resulting of this issue. An internal technical investigation confirmed that the products below may report incorrect AST results during quality control.
2.	2. Hazard giving rise to the FSCA* Incorrect AST results during quality control.
2.	3. Probability of problem arising High
2.	4. Predicted risk to patient/users There should be moderate health consequences for patients when laboratories ignore Quality Control test results. From a clinical perspective, antifungal susceptibility testing should be considered only a guide. The likelihood of antifungal agents being associated with serious life-threatening consequences should be considered relatively low, possibly associated with delayed response or the need to change to another agent.

Rev 1: September 2018
FSN Ref: FSN-2026-003

2.	5. Further information to help characterise the problem
	N/A
2.	6. Background on Issue
	Nine customers reported performance issues of Yeastone Broth, 11ml, 10/Box, YY3462, lots 321046, 329835, 330316, 327069, 330317, 336325, 338314, 341161, 303851, 311723.
2.	7. Other information relevant to FSCA
	N/A

3. Type of Action to mitigate the Risk*		
3.	1. Action To Be Taken by the User* ☒ Identify Device ☐ Quarantine Device ☐ Return Device ☒ Destroy Device ☐ On-site device modification/inspection ☒ Follow patient management recommendations ☐ Take note of amendment/reinforcement of Instructions For Use (IFU) ☐ Other ☐ None	
3.	2. By when should the action be completed?	Immediately
3.	3. Particular considerations for: IVD Is follow-up of patients or review of patients' previous results recommended? Yes Review results.	
3.	4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes
3.	5. Action Being Taken by the Manufacturer ☒ Product Removal ☐ On-site device modification/inspection ☐ Software upgrade ☐ IFU or labelling change ☐ Other ☐ None	
3	6. By when should the action be completed?	Immediately
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet? N/A Choose an item.	

Rev 1: September 2018
FSN Ref: FSN-2026-003

4. General Information*		
4.	1. FSN Type*	New
4.	2. For updated FSN, reference number and date of previous FSN	N/A
4.	3. For Updated FSN, key new information as follows:	N/A
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet
4	5. If follow-up FSN expected, what is the further advice expected to relate to:	N/A
4	6. Anticipated timescale for follow-up FSN	N/A
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Thermo Fisher Scientific
	b. Address	Confidential business information [Redacted] [Redacted] [Redacted]
	c. Website address	www.thermofisher.com
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. Yes	
4.	9. List of attachments/appendices:	Customer response form
4.	10. Name	Personal data [Redacted]
	Signature	Personal data [Redacted]

Transmission of this Field Safety Notice	
	This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate) Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action. Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*

Rev 1: September 2018
FSN Ref: FSN-2026-003

Customer Reply Form

1. Field Safety Notice (FSN) information			
FSN Reference number*	2026-003		
FSN Date*	31 March 2026		
Product/ Device name*	Yeastone Broth 11ML, 10/Box		
Product Code(s)	YY3462		
Batch/Serial Number (s)	321046; 329835; 330316; 327069; 330317; 336325; 338314; 341161; 303851; 311723		
2. Customer Details			
Account Number			
Organisation Name*			
Organisation Address*			
Department/Unit			
Shipping address if different to above			
Contact Name*			
Title or Function			
Telephone number*			
Email*			
3. Customer action undertaken on behalf of Healthcare Organisation			
☐	I confirm receipt of the Field Safety Notice and that I read and understood its content.		
☐	I performed all actions requested by the FSN.		
☐	The information and required actions have been brought to the attention of all relevant users and executed.		
☐	I have returned affected devices - enter number of devices returned and date complete N/A	Qty:	Lot/Serial Number: Date Returned (DD/MM/YY)
		Comments:	
☐	I have destroyed affected devices – enter number destroyed and date complete.	Qty:	Lot/Serial Number: Date Completed (DD/MM/YY)
		Qty	Credit ☐ Replacement ☐
		Comments:	
☐	No affected devices are available for return/ destruction		
☐	Other Action (Define):		
☐	I do not have any affected devices.		
☐	I have a query please contact me (e.g. need for replacement of the product).		
Print Name*			
Signature*			
Date*			
4. Return acknowledgement to sender			
Email	Confidential business information		
Deadline for returning the reply form*	28 April 2026		

Mandatory fields are marked with *

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN. Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.